A study of the efficacy and safety of CMA-676 [gemtuzumab ozogamicin] as single agent treatment of patients with acute myeloid leukemia (AML) in first relapse
Phase of Trial: Phase II
Latest Information Update: 29 Sep 2005
At a glance
- Drugs Gemtuzumab ozogamicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 29 Sep 2005 New trial record.